D
Hemostemix Inc. HMTXF
$0.04 $0.000.80% OTC PK
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
Corporate Info
Phone Number
--
Address
707-7th Avenue SW
Suite 1150
Calgary, AB T2P 3H6
Country
Canada
Year Founded
--
Details
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Employees
Business Description
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.